logo-loader
viewImpediMed

ImpediMed is cheered by North Carolina decision on health plan coverage of lymphoedema

au_bio350_4a6e699c47389.jpg

ImpediMed (ASX: IPD) has received significant cheer from a decision by the state of North Carolina in the US on health plan coverage of the diagnosis, evaluation, and treatment of lymphoedema.

The General Assembly in North Carolina ratified House Bill 535 of Session 2009, mandating that every health benefit plan shall provide coverage for the diagnosis, evaluation, and treatment of lymphoedema.

ImpediMed had the first medical device with an FDA clearance in the United States to aid health care professionals in the clinical assessment of secondary lymphoedema of the arm in female breast cancer patients.

ImpediMed’s L-Dex product is used as an aid in the clinical assessment of patients at risk of lymphoedema.

Chief Executive Officer of ImpediMed, Greg Brown said the legislation should encourage the adoption of a pre-emptive care approach to monitoring patients at risk of lymphoedema, by supporting medical providers in the reimbursement for the diagnosis and evaluation of lymphoedema.

Brown said, ”this is ground breaking legislation that goes further than any other US federal or state legislation has previously gone.

Further, the company said, “not only does this legislation support North Carolina medical providers today in adopting ImpediMed’s technology for use with patients at risk of lymphoedema through breast cancer treatment, it also begins to pave the way for reimbursement for patients at risk of lymphoedema through pelvic region cancers, for which the patient numbers are considerably higher than breast cancer."

ImpediMed expects to submit applications for FDA clearance of its L-Dex U400 device for use in the clinical assessment of unilateral leg lymphoedema by the 3rd quarter of 2010, and for use in the clinical assessment of bilateral leg lymphoedema by the 1st quarter of 2011.

Quick facts: ImpediMed

Price: 0.067 AUD

ASX:IPD
Market: ASX
Market Cap: $67.34 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Australian Vanadium confirms ‘exceptional’ vanadium extraction in test work

Australian Vanadium Ltd (ASX:AVL) (OTCMKTS:ATVVF) managing director Vincent Algar speaks to Proactive about recent pilot test-work conducted at the Australian Vanadium Project, which delivered leach extraction of up to 94.7%. The pilot-scale roast and leach testing has confirmed the...

1 day, 6 hours ago

2 min read